Adcentrx Therapeutics

Company Drug

Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors

Fineline Cube Jun 9, 2026

Adcentrx Therapeutics announced today that China’s National Medical Products Administration (NMPA) has cleared the company’s...

Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Company Drug

Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136

Company Drug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market